Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial-Reference-Cited by-同舟云学术

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Published:1999-12 Issue:9194 Volume:354 Page:1932-1939
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Maini Ravinder,St Clair E William,Breedveld Ferdinand,Furst Daniel,Kalden Joachim,Weisman Michael,Smolen Josef,Emery Paul,Harriman Gregory,Feldmann Marc,Lipsky Peter

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Methotrexate in rheumatoid arthritis: a five year prospective study.;Weinblatt;Arthritis Rheum,1994

2. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.;Maetzel;J Rheumatol,1998

3. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis.;Tugwell;N Engl J Med,1995

4. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination-of all three medications.;O'Dell;N Engl J Med,1996

5. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.;Wolfe;J Rheumatol,1990

Cited by 2017 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis;Nature Reviews Rheumatology;2024-09-06

2. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation;The AAPS Journal;2024-07-24

3. Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-11

4. Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development;Expert Opinion on Investigational Drugs;2024-07-09

5. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease;Annals of the Rheumatic Diseases;2024-07-04